Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Santhera Pharmaceuticals Holding AG's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.46.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Santhera Pharmaceuticals Holding AGcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Santhera Pharmaceuticals Holding AG Cash-to-Debt Related Terms
Santhera Pharmaceuticals Holding AG Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Santhera Pharmaceuticals Holding AG Cash-to-Debt Chart
XSWX:SANN vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a Cash-to-Debt of 0.46 as of Dec. 2025. This is 10% below median its historical median of 0.51. Over the past decade, Santhera Pharmaceuticals Holding AG's Cash-to-Debt has ranged from 0.03 to 10,000.00. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #1203 out of 1398 companies in the Biotechnology industry, placing it in the top 86.1%.
Is Santhera Pharmaceuticals Holding AG's Cash-to-Debt too high?
Santhera Pharmaceuticals Holding AG's current Cash-to-Debt of 0.46 is 10% below median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.21. Santhera Pharmaceuticals Holding AG's value of 0.46 is 92.6% below this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #1203 out of 1398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #1203 out of 1398 companies for Cash-to-Debt. This places Santhera Pharmaceuticals Holding AG in the lower half of its industry. The industry median Cash-to-Debt is 6.21. Santhera Pharmaceuticals Holding AG's value of 0.46 is 92.6% below this benchmark. Historically, Santhera Pharmaceuticals Holding AG's own Cash-to-Debt has ranged from 0.03 to 10,000.00 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 6.21, Santhera Pharmaceuticals Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Cash-to-Debt of 0.46 is 92.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Cash-to-Debt is 0.46, which is 10% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF25.24, compared to a current price of CHF15.84 — trading 37.2% below its estimated fair value. The current Cash-to-Debt is 0.46, which is 10% below median its 10-year median of 0.51 and 92.6% below the Biotechnology industry median of 6.21. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current Cash-to-Debt is 0.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of CHF15.84 is trading 37.2% below its estimated GF Value™ of CHF25.24.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.
Key valuation signals for XSWX:SANN:
Cash-to-Debt: 0.46 (10% below median its 10-year median of 0.51)
GF Value™: CHF25.24 vs. price of CHF15.84 (37.2% below fair value)
Industry Position: 92.6% below the Biotechnology median (#1203 of 1398)
No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
34GF Score
Get the complete analysis for XSWX:SANN
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SANN has been successfully added to your 
